Search Results - "Malinge, Laure"

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis by Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee

“…The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory…”
Get full text

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis by Capra, Marcelo, Martin, Thomas, Moreau, Philippe, Baker, Ross, Pour, Ludek, Min, Chang-Ki, Leleu, Xavier, Mohty, Mohamad, Segura, Marta Reinoso, Turgut, Mehmet, LeBlanc, Richard, Risse, Marie-Laure, Malinge, Laure, Schwab, Sandrine, Dimopoulos, Meletios

“…Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study…”
Get full text

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study by Richardson, Paul G, Perrot, Aurore, San-Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A, Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H Miles, Malinge, Laure, Dubin, Franck, van de Velde, Helgi, Anderson, Kenneth C

“…The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to…”
Get full text

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies by Richardson, Paul G., Perrot, Aurore, San-Miguel, Jesús, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey SY, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Macé, Sandrine, Malinge, Laure, Dubin, Franck, Morisse, Mony, Anderson, Kenneth C.

Get full text

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis by Capra, Marcelo, Martin, Thomas, Moreau, Philippe, Baker, Ross, Pour, Ludek, Min, Chang-Ki, Leleu, Xavier, Mohty, Mohamad, Reinoso Segura, Marta, Turgut, Mehmet, Leblanc, Richard, Risse, Marie-Laure, Malinge, Laure, Schwab, Sandrine, Dimopoulos, Meletios A

“…Introduction: Renal impairment (RI) is a common feature in multiple myeloma (MM) and an adverse predictor of survival. Anti-myeloma treatments that can also…”
Get full text

OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis by Richardson, Paul, Perrot, Aurore, San-Miguel, Jesus, Beksac, Meral, Špička, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H Miles, Malinge, Laure, Dubin, Franck, Morisse, Mony, Anderson, Kenneth

Get full text

Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis by Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Attal, Michel, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Prince, H. Miles, Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, van de Velde, Helgi, Yong, Kwee

Get full text